cm326
mAbexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Apr 16, 2021 (NCT04842201)
Timeline
Indications
Mechanism of action
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06372678 | Phase 2 | Jun 30, 2024 | Capital Medical University, Keymed Biosciences Co.Ltd |
| NCT05774340 | Phase 2 | May 18, 2023 | Shijiazhuang Pharma Group (CSPC) |
| NCT05715333 | Phase 1 | Mar 21, 2023 | Keymed Biosciences Co.Ltd, Peking University |
| NCT05671445 | Phase 2 | Feb 9, 2023 | Keymed Biosciences Co.Ltd |
| NCT05671432 | Phase 2 | Dec 27, 2022 | Keymed Biosciences Co.Ltd |
| NCT05324137 | Phase 1/Phase 2 (Phase 2) | Aug 30, 2022 | Capital Medical University, Keymed Biosciences Co.Ltd |
| NCT05186922 | Phase 1/Phase 2 (Phase 2) | Feb 17, 2022 | Keymed Biosciences Co.Ltd |
| NCT05171348 | Phase 1 | Jan 7, 2022 | Keymed Biosciences Co.Ltd |
| NCT04842201 | Phase 1 | Apr 16, 2021 | Keymed Biosciences Co.Ltd, PKUcare luzhong hospital |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Keymed Biosciences Co.Ltd | For profit | 8 | 8 | 2 | 2021 |
| Capital Medical University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| PKUcare luzhong hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1